Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.

The relative simplicity and high specificity of peptide therapeutics has fueled recent interest. However, peptide and protein drugs generally require injection and suffer from low metabolic stability. We report here the design, synthesis, and characterization of fluorinated analogues of the gut hormone peptide, GLP-1. Overall, fluorinated GLP-1 analogues displayed higher proteolytic stability with simultaneous retention of biological activity (efficacy). Fluorinated amino acids are useful for engineering peptide drug candidates and probing ligand-receptor interactions.

[1]  A. Ramamoorthy,et al.  Using Fluorous Amino Acids to Modulate the Biological Activity of an Antimicrobial Peptide , 2008, Chembiochem : a European journal of chemical biology.

[2]  S. Purser,et al.  Fluorine in medicinal chemistry. , 2008, Chemical Society reviews.

[3]  Krishna Kumar,et al.  Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. , 2007, Journal of the American Chemical Society.

[4]  F. Diederich,et al.  Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.

[5]  C. Wood,et al.  Therapeutic peptides: technological advances driving peptides into development. , 2006, Current opinion in biotechnology.

[6]  R. P. Cheng,et al.  Helix propensity of highly fluorinated amino acids. , 2006, Journal of the American Chemical Society.

[7]  G. Asensio,et al.  The introduction of fluorine atoms or trifluoromethyl groups in short cationic peptides enhances their antimicrobial activity. , 2006, Bioorganic & medicinal chemistry.

[8]  C. Bailey,et al.  Novel Glucagon-Like Peptide-1 (GLP-1) Analog (Val8)GLP-1 Results in Significant Improvements of Glucose Tolerance and Pancreatic β-Cell Function after 3-Week Daily Administration in Obese Diabetic (ob/ob) Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[9]  A. Kopin,et al.  A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness , 2005, Regulatory Peptides.

[10]  G. Scapin,et al.  (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.

[11]  E. Marsh,et al.  Fluorous effect in proteins: de novo design and characterization of a four-alpha-helix bundle protein containing hexafluoroleucine. , 2004, Biochemistry.

[12]  J. Holst,et al.  Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. , 2004, Current opinion in pharmacology.

[13]  L. B. Knudsen.  Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. , 2004, Journal of medicinal chemistry.

[14]  C. Sarrauste de Menthière,et al.  Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production. , 2004, European journal of medicinal chemistry.

[15]  Justin C. Biffinger,et al.  The Polar Hydrophobicity of Fluorinated Compounds , 2004, Chembiochem : a European journal of chemical biology.

[16]  C. Bailey,et al.  Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). , 2004, Metabolism: clinical and experimental.

[17]  C. Bailey,et al.  Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. , 2003, Journal of molecular endocrinology.

[18]  D. Donnelly,et al.  A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptors , 2003, British journal of pharmacology.

[19]  P. Proost,et al.  A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro. , 2002, Biochemical pharmacology.

[20]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[21]  M. Beinborn,et al.  A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. , 2001, The Journal of biological chemistry.

[22]  D. Drucker.  Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. , 2001, Current pharmaceutical design.

[23]  D. Tirrell,et al.  Self-association and membrane-binding behavior of melittins containing trifluoroleucine. , 2001, Journal of the American Chemical Society.

[24]  M. Wheeler,et al.  Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. , 2001, Biochemistry.

[25]  L. B. Knudsen,et al.  Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. , 2000, Journal of medicinal chemistry.

[26]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[27]  G. Ramadori,et al.  A synthetic glucagon-like peptide-1 analog with improved plasma stability. , 1998, The Journal of endocrinology.

[28]  J. Holst,et al.  Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity , 1998, Diabetologia.

[29]  B. Göke,et al.  The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action. , 1997, Endocrine journal.

[30]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[31]  D. Wong,et al.  Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. , 1995, Life sciences.

[32]  D. Gorenstein,et al.  Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. , 1994, Biochemistry.

[33]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[34]  H. Yoo-Warren,et al.  Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. , 1993, Endocrinology.

[35]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[36]  B. Huber,et al.  Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  G. Marshall,et al.  Long-acting angiotensin II inhibitors containing hexafluorovaline in position 8. , 1987, Journal of medicinal chemistry.

[38]  G. Marshall,et al.  SYNTHESIS OF FLUORINE-CONTAINING PEPTIDES. ANALOGS OF ANGIOTENSIN II CONTAINING HEXAFLUOROVALINE , 1982 .

[39]  G. Marshall,et al.  Synthesis, biological activity, and 19 F nuclear magnetic resonance spectra of angiotensin II analogs containing fluorine. , 1973, Biochemistry.

[40]  D. Yach,et al.  Epidemiologic and economic consequences of the global epidemics of obesity and diabetes , 2006, Nature Medicine.

[41]  R. Pederson,et al.  [Ser 2 ]- and [Ser(P) 2 ]Incretin Analogs COMPARISON OF DIPEPTIDYL PEPTIDASE IV RESISTANCE AND BIOLOGICAL ACTIVITIES IN VITRO AND IN VIVO * , 2004 .